Clinical outcome of patients with relapsed/refractory acute leukemia treated with FLAG-IDA regimen
Hematología (B. Aires)
; 13(2): 49-52, mayo-ago. 2009. tab, graf
Article
in En
| BINACIS
| ID: bin-124594
Responsible library:
AR67.1
Localization: AR67.1
ABSTRACT
Background:
Patients with Refractory/Relapsed (RIR) acute leukemia (AL) have a poor prognosis.Objective:
We aimed to evaluate the chemotherapy regimen fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) in patients with RIR AL. Patients We studied 33 patients with R/R AL. Distribution of the AL subtype was myeloblastic n=17 (52%), lymphoblastic n=14 (42%),) and biphenotypic n=2 (6%).Results:
Complete remission (CR) was achieved in 15 cases (45.5%) and seven patients dead resulting in a mortality of 21.1%. In patients with hematological recovery the median time to neutrophils recovery (> 0.5 x 10º/1) was 24 days (range 10-38); platelet levels of more than 20 x 1Oº/l and 50 x 10º/1 were reached in a median time of 24 (range 17-44) and 27 days (range 18-51), respectively. After CR, five patients underwent allogeneic transplan- tation and 10 patients
Search on Google
Collection:
06-national
/
AR
Database:
BINACIS
Main subject:
Transplantation
/
Leukemia
Type of study:
Prognostic_studies
Language:
En
Journal:
Hematología (B. Aires)
Year:
2009
Document type:
Article
Country of publication:
Argentina